L½,&E¬' M78 E¬f

22
2

Transcript of L½,&E¬' M78 E¬f

Page 1: L½,&E¬' M78 E¬f

2

Page 2: L½,&E¬' M78 E¬f

Glycemic control

Date OHA regimen HbA1c plasma glucose (mg/dL)

2003/10/7 Metformin 10.2 AC: 138PC: 487

2004/2/27 Amaryl + Metformin one touch: >300

2005/11/23 Amaryl + Metformin AC: 137

2006/6/1 Metformin + Acarbose + Repaglinide 14.2

2006/10/31 Metformin + Acarbose + Gliclazide 7.9

Page 3: L½,&E¬' M78 E¬f
Page 4: L½,&E¬' M78 E¬f
Page 5: L½,&E¬' M78 E¬f
Page 6: L½,&E¬' M78 E¬f
Page 7: L½,&E¬' M78 E¬f

––––

Kaplan-Meier plot of tuberculosis-free survival by diabetes mellitus and glycemic control status, adjusted for age

p-value from log-rank test for overall difference: 0.0019

14

poor glycemic control (FPG>130 mg/dL)

Page 8: L½,&E¬' M78 E¬f

Results from Cox proportional hazards regression model for association between diabetes status, glycemic control, and risk of TB

15

Dose-response curves for fasting plasma glucose and risk of incident tuberculosis in the Cox proportional hazards model

16

p

Page 9: L½,&E¬' M78 E¬f

Subgroup Analysis or Diabetes Status and Risk of TB

BMI and gender: not statistically significant effect modifiers

Page 10: L½,&E¬' M78 E¬f

Baker et al, BMC Medicine 2011, 9:81

Lee et al, Plos one 2014

20

Page 11: L½,&E¬' M78 E¬f

–•

21

••••

22

( ):

WHO: Collaborative framework for care and control of TB and DM

Page 12: L½,&E¬' M78 E¬f

2018

––

––

––

Page 13: L½,&E¬' M78 E¬f

•–

––

25

2018

Page 14: L½,&E¬' M78 E¬f

••

••

•–

27

28

Page 15: L½,&E¬' M78 E¬f

••

•––

29

•–

–•

30

Page 16: L½,&E¬' M78 E¬f

31

2018

PDF: http://www.thearc.org.au/Resources/Uploaded/Resources/21812%20-%20ARC%20TB%20Diabetes%20Flipchart%20-%20WEB.pdf

Page 17: L½,&E¬' M78 E¬f

DM-TB co-management: from evidence to action…

34

A1C : every 3 months

1% solution:

Page 18: L½,&E¬' M78 E¬f

1 2 3 4 5 6

Intensive phase Continuation phase

HERZ HR(E)•

:

40

Page 19: L½,&E¬' M78 E¬f

Page 20: L½,&E¬' M78 E¬f

Page 21: L½,&E¬' M78 E¬f

Page 22: L½,&E¬' M78 E¬f

43

Thanks for your attention!

[email protected]